Labcorp Holdings Inc. (LH) fair value analysis
S&P 500 · Updated 2026-10-19
LH price how computed
Forward Fair Value verdict
Fairly valuedLH is trading at within about 10% of estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $312.15
- Sector
- Healthcare
- 12-month range
- $246.64–$339.34
- Market cap
- $25.3B
- From 52-week high
- -8.0%
- Shares outstanding
- 81.1M
- Rank in Healthcare by discount to fair value
- #69 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Labcorp Holdings Inc. is a clinical laboratory and drug development services company that provides diagnostic testing, drug development solutions, and related services to healthcare providers, patients, and pharmaceutical companies. The company operates laboratories and service centers throughout the United States and internationally in multiple countries.
LH currently ranks #69 of 108 Healthcare stocks by discount to fair value. It has screened as Fairly valued for 11 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $25.3B
- P/E (trailing)
- 18x
- Revenue (TTM)
- $14.3B
- Net margin
- 7.0%
- EPS (TTM)
- $17.49
- Gross margin
- 29.8%
- Debt / equity
- 0.79
- Revenue growth (3-yr avg)
- 7.4%
- Shares outstanding
- 81.1M
Derived indicators how computed
- Quality grade
- D
- Margin trend
- Stable
- 52-week position
- The upper-middle quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 48 · neutral
- 50-day average
- $320.43
- 200-day average
- $283.39
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Dividends how computed
- Paid, last 12 months
- $2.88 per share (4 payments)
- Yield on last price
- 0.92%
- Consecutive years of increases
- 0 (no streak on complete calendar years)
- Last ex-dividend date
- 2026-08-28
- Last payment date
- 2026-09-11
Earnings how computed
- Next earnings report
- 2026-10-28 (pre-market)
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+4.2%)
2026-03 ▲ beat (+3.2%)
2025-12 ▲ beat (+3.3%)
2025-09 ▲ beat (+1.0%)
2025-06 ▲ beat (+4.6%)
2025-03 ▲ beat (+2.9%)
2024-12 ▲ beat (+1.8%)
2024-09 ▲ beat (+0.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 13 buy · 4 hold · 1 sell (18 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $345
- Target vs last price
- +10.5%
What our data shows for LH
- Our model validated 17 trailing price-to-earnings windows for LH, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $246.64–$339.34.
- The 14-day relative strength index sits at a neutral 48.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for LH
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent LH news
TickrTrends' derived news-sentiment signal for LH is currently leaning positive, computed from recent coverage.
- UpGrad completes Unacademy acquisition; Ultrahuman’s $60 million raise (economictimes.indiatimes.com, 2026-09-01)
TickrTrends take: I cannot write the requested analysis because the headline provided discusses UpGrad, Unacademy, and Ultrahuman, which are companies in the education and technology sectors, while the assignment requires me to relate this news to LH (LaboratoryLaboratories), a healthcare company. There is no factual connection between the headline and LH that would allow me to write accurate, factual prose for a stock research page. To provide appropriate analysis, I would need a headline or news item that actually pertains to LH or its competitive environment in healthcare.
What people are saying
Follow the LH conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends' derived indicators for LH shifted the valuation verdict from Fairly valued to Overvalued this week. This change reflects a deterioration in LH's valuation metrics within the Healthcare sector. The stock is now trading at levels that TickrTrends' analysis suggests exceed fair value based on its current fundamental indicators.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is LH stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), LH is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.
What is LH's TickrTrends verdict?
LH's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.
How does LH compare to other Healthcare stocks?
LH ranks #69 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is LH overbought or oversold?
LH's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does LH pay a dividend?
Yes. LH paid $2.88 per share over the last twelve months (4 payments), a 0.92% yield on TickrTrends' last price. The last ex-dividend date was 2026-08-28.
When does LH report earnings next?
LH's next earnings report is scheduled for 2026-10-28 (pre-market), per the published earnings calendar.
Does LH usually beat earnings estimates?
Over its last 8 reported quarters LH beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about LH?
Of 18 analysts covering LH, 13 rate it a buy, 4 a hold and 1 a sell - buy-leaning, with a consensus price target of $345 (+10.5% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
LH vs ACAD · LH vs BIIB · LH vs BMY · LH vs BVS · LH vs ELV